SEC Filing Summary

Philip Hodges, a director at Altimmune, Inc. (ALT), was granted 48,800 stock options on May 1, 2026. These options, exercisable at $2.82 per share, vest over 12 months, with vesting contingent upon continued service. The options were issued under the company's non-employee director compensation policy and expire on May 1, 2036.